Pearl Therapeutics, Inc.: Series C $15M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Feb

2010

Flexion Therapeutics, Inc.: Series A $9M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Autoimmune, X - IBD, X - Tinnitus, XX - MA

Flexion Therapeutics (Woburn, MA) a clinical-stage biopharma focused on autoimmune disease, ulcerative colitis and tinnitus, closed a $9M Series A financing, bringing the total round to $42M. Participants include Pfizer Venture Investments, Versant Ventures, 5AM Ventures and Sofinnova Ventures.

Jan

2010

Pulmatrix, Inc.: Series B $30.2M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Jan

2010

Flexion Therapeutics, Inc.: Series A $33M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Specialty Pharma, XX - MA

Flexion Therapeutics (Woburn, MA) advances high value specialty drug candidates through clinically meaningful proof of concept and beyond, the company plans to announce deals with three major pharmas shortly, closed a $33M Series A financing. Participants include Versant Ventures, 5AM Ventures and Sofinnova Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...